Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

NCT04409639 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG: Cobimetinib

Sponsor

University of Utah

Collaborators

[object Object]